SEC Form 4 · accession 0001209191-17-048677
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew N Schiff
Director
Period of report
Aug 9, 2017
Accepted (ET)
Aug 14, 2017 · 8:21 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $26.97 | Aug 9, 2017 | A | 16,000 | A | — | Aug 8, 2027 | Common Stock | 16,000 | 16,000 | D |
Explanation of responses
- F1This option will vest and become exercisable in 36 equal monthly installments through August 9, 2020, subject to the reporting person's continuous service as of such vesting dates.